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background:  Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors are an effective strategy for lowering LDL-C. In an oral 
presentation from our group, we reported that PCSK9 is elevated in HIV infection, a state of heightened inflammation. Here, we aim to 
characterize the levels of PCSK9 in individuals with HIV and Hepatitis C (HCV) co-infection, another hyper-inflammatory state that may 
also impact the ability of hepatocytes to synthesize PCSK9.
Methods:  We measured PCSK9 in 567 participants (111 HIV+/HCV+, 385 HIV+, 72 controls) from an outpatient cohort in San Francisco 
using a high affinity ELISA assay. Poisson regression models were used to determine associations between HIV/HCV and PCSK9 levels.
results:  The median age was 50 years (IQR 43-55) and 89% were male; 34% were smokers, 25% hypertensive, median LDL was 103 
mg/dL (IQR 80-127), and 21% were on statins. HIV patients and controls had similar rates of traditional risk factors. Half of the HIV patients 
were treated and suppressed. PCSK9 levels were 21% higher in HIV/HCV co-infected patients vs. controls (95% CI 1.09-1.34) and 11% 
higher in co-infected patients vs. those with HIV alone (95% CI 1.03-1.20). In a fully adjusted model, HIV/HCV co-infection retained a highly 
significant association with 21% higher PCSK9 levels (95% CI 1.09-1.34, p=0.001) (Table).
conclusion:  PCSK9 is significantly increased in HIV and HCV co-infection. Future studies should explore whether PCSK9 inhibition may 
be used safely to treat dyslipidemia in such patients.
 
